Recurrent Childhood Soft Tissue Sarcoma: Clinical Trials

8 trials for Recurrent Childhood Soft Tissue Sarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 recruiting, 1 terminated. 8 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 18Completed 6, Recruiting 1, Terminated 1

Follow Recurrent Childhood Soft Tissue Sarcoma: new trials by email Literature Review of Recurrent Childhood Soft Tissue Sarcoma trials Research Report on Recurrent Childhood Soft Tissue Sarcoma

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Functional Precision Medicine - Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
Phase 1RecruitingFlorida International University652023-02-222026-08-26
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
Bevacizumab, Cetuximab, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Castleman Disease
Phase 1TerminatedM.D. Anderson Cancer Center1162012-10-162026-11-05
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
pazopanib hydrochloride, pharmacological study - Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor
Phase 1CompletedNational Cancer Institute (NCI)552009-06-012013-09-30
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Cixutumumab, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor
Phase 1CompletedNational Cancer Institute (NCI)302008-06-012016-05-17
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
irinotecan hydrochloride, oxaliplatin - Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor
Phase 1CompletedNational Cancer Institute (NCI)242005-03-012013-06-05
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
tanespimycin, pharmacological study, laboratory biomarker analysis - Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor
Phase 1CompletedNational Cancer Institute (NCI)702004-09-012013-06-04
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
erlotinib hydrochloride, temozolomide, pharmacological study - Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor
Phase 1CompletedNational Cancer Institute (NCI)952004-02-012013-06-05
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
alvocidib, pharmacological study - Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma
Phase 1CompletedNational Cancer Institute (NCI)302001-04-012013-07-02

Narrower conditions

Familial ependymoma (4)  ·  Neuroblastoma (4)  ·  Osteosarcoma (4)  ·  Astrocytoma (3)  ·  Dendritic Cell Sarcoma, Interdigitating (3)  ·  Medulloblastoma (3)  ·  Neuroectodermal Tumors, Primitive, Peripheral (3)  ·  Optic Nerve Glioma (3)  ·  Recurrence (3)  ·  Burkitt Lymphoma (2)  ·  Desmoplastic Small Round Cell Tumor (2)  ·  Neoplasms (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Sarcoma (2)  ·  Wilms Tumor (2)

Broader conditions

Neoplasms by Histologic Type (8)  ·  Neoplasms, Nerve Tissue (7)  ·  Neoplasms (6)  ·  Neoplasms, Connective and Soft Tissue (6)  ·  Neoplasms, Germ Cell and Embryonal (6)  ·  Neoplasms, Glandular and Epithelial (6)  ·  Neuroectodermal Tumors (6)  ·  Hemic and Lymphatic Diseases (5)  ·  Immune System Diseases (5)  ·  Immunoproliferative Disorders (5)  ·  Lymphatic Diseases (5)  ·  Lymphoproliferative Disorders (5)  ·  Neoplasms, Connective Tissue (5)  ·  Neoplasms, Neuroepithelial (5)  ·  Nervous System Diseases (5)

Interventions

Bevacizumab (1)  ·  Cetuximab (1)  ·  Disulfides (1)  ·  Doxorubicin (1)  ·  Erlotinib Hydrochloride (1)  ·  Immunoglobulin G (1)  ·  Irinotecan (1)  ·  Oxaliplatin (1)  ·  Sirolimus (1)  ·  Temozolomide (1)  ·  Valproic Acid (1)  ·  alvocidib (1)  ·  cixutumumab (1)  ·  pazopanib (1)  ·  tanespimycin (1)

Sponsors

National Cancer Institute (NCI) (6)  ·  Florida International University (1)  ·  M.D. Anderson Cancer Center (1)

Countries

United States (8)

Top investigators

Diana Azzam (1)  ·  James Whitlock (1)  ·  Julia Glade-Bender (1)  ·  Lisa McGregor (1)  ·  Maggie Fader (1)  ·  Rashmi Chugh (1)  ·  Regina Jakacki (1)  ·  Sarina A Piha-Paul (1)  ·  Tanya Trippett (1)

Results publications

PMID 23857966, PMID 25858498, PMID 26933802, PMID 37311055, PMID 41389341

NIH funding

U01CA097452 (4), N01CM00071 (1), P30CA014599 (1), U01CA069856 (1), U54MD012393 (1)